Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
During dose escalation The first few weeks on any GLP-1 medication are the riskiest for side effects
Yes the transition can be made between the obesity-approved versions (Zepbound to Wegovy) or the diabetes-approved versions (Mounjaro to Ozempic), depending on your diagnosis and your providers prescription
Safety issues with glucagonlike peptide1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials
If you're considering Mounjaro vs Zepbound, remember that Mounjaro for type 2 diabetes is not supported through telehealth due to the need for in-person monitoring and lab work
65 WhartonS.LauD
Additionally, the side effects may be worse in the weeks that you increase your dose
US$ 23.85
US$ 26.37
US$ 29.54
US$ 23.70
